Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Medico-economic Evaluation Rehabilitation by Serious Games at Home for the Management of Patients With Parkinson's Disease Suffering From Gait and Balance Disorders

NCT04720365 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2023-02-15
Last updated
2026-02-06

Condition(s) studied

Patients With Parkinson's Disease

Investigational drug(s) / intervention(s)

play-based rehabilitaion

play-based rehabilitaion: usual re-education treatment by their physiotherapist

Study summary

This is a multi-center, randomized, open-label, multi-center, randomized controlled study of 80 Parkinson's disease patients with gait and balance disorders in which 40 patients will be treated with serious games, in addition to their usual care, for 12 months and 40 patients will be treated with their usual care during this period. This study will be conducted in 4 centers, all of which are expert in the management of these patients.

After randomization, each patient in the "Intervention-Rehabilitation through Toap Run" group will have to complete 2 to 3 sessions per week at home with the serious game "TOAP RUN" using the Kinect® system for 1 year.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Diagnosis of idiopathic Parkinson's disease (according to United Kingdom Parkinson's Disease Society Brain Bank \[UKPDD\] criteria) ; 2. Age ≥ 18 years ; 3. Patient with gait and/or balance disorders not improved by levodopa treatment with item 12 "walking and balance" ≥ 1 of the MDS-UPDRS (Movement-Disorders Society-Unified Parkinson's disease rating scale) part II, ON levodopa and/or item 13 of "gait freezing" ≥ 1 (Goetz, Tilley et al. 2008); 4. Number of falls ≥ 2 in the previous year; 5. Stable antiparkinsonian treatments for at least 1 month prior to inclusion in the study ; 6. Patient with social health insurance ; 7. Person who voluntarily and informedly agreed to participate in the study (signed written consent) ; 8. Other medical problems that are stable or do not interfere with the proposed protocol; Exclusion Criteria: 1. Parkinson's disease with Hoehn\&Yahr stage 5 corresponding to an inability of the subject to stand or walk alone ; 2. Dementia (MMS \< 24 and/or MoCA \< 18) ; 3. Presence of an impulse control disorder defined by item 6 of the MDS-UPDRS part I \> 2 ; 4. Absence of internet connection at home ; 5. Serious pathology interfering with the test ; 6. Estimated life expectancy of less than 2 years ; 7. Subject in a period of exclusion from further research ; 8. Persons under guardianship, curatorship or any other administrative or judicial measure of deprivation of rights and liberty ; 9. Pregnant woman or woman of childbearing age without contraceptive methods;

Primary outcome measure(s)

  • The incremental cost-utility ratio at 12 months for the management of patients with Parkinson's disease using therapeutic games — at 12 months for the management of patients with Parkinson's disease using therapeutic games
    The result criterion is the additional cost in euros of a QALY gained. The QALY will be calculated from the utilities derived from the EuroQuality scale of life-5 dimensions EQ5D-3L.

Trial sites (4)

FacilityCityRegionStatus
Chu Bordeaux Bordeaux France Recruiting
Chu Lille Lille France Recruiting
Gh Pitie Salpetriere Paris France Recruiting
Rouen University Hospital Rouen France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04720365 on ClinicalTrials.gov ↗ ← All trials in France